Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction(KSCC 1601) - Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction(KSCC 1601)

Kyushu Study group of Clinical Cancer0 个研究点目标入组 47 人开始时间: 2016年2月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Severe drug hypersensitivity (particularly to platinum analogs, 5-FU, or S-1) 2) Peripheral neuropathy affecting the sensory nerves (Grade 1 or worse) 3) Active infection 4) Uncontrollable hypertension 5) Uncontrollable diabetes mellitus or routine administration of insulin 6) Heart disease that may pose a problem 7) Severe pulmonary disease 8) Severe mental disease 9) Active gastrointestinal tract bleeding requiring repeated transfusions 10) Under treatment with phenytoin, warfarin or flucytosine 11) Watery diarrhea (Grade 2 or worse) 12) Synchronous or metachronous malignancies other than carcinoma in situ or mucosal cancer 13) A woman who is pregnant, nursing, or possibly pregnant or a man who is trying to conceive with a partner 14) Cirrhosis or hepatitis 15) Patients judged by the investigator as unfit to be enrolled in the study.

发起方

Kyushu Study group of Clinical Cancer